WARSAW, Ind., Dec. 2 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. , a worldwide leader in the orthopaedics industry, announced today it has entered into a distribution agreement with Baxter Healthcare Corporation that will allow Zimmer to market Baxter's Infusor as part of a pain management kit for orthopaedic and other non-oncology surgical procedures in the United States.
"This is another demonstration of Zimmer's determination to be a provider of solutions for orthopaedic surgery that improve the patient's overall experience," said Ray Elliott, Zimmer Chairman, President and Chief Executive Officer. "Many surgeons believe the patient is able to rehabilitate faster if pain management begins at the surgical site, and we are pleased to work with Baxter to offer a system that helps them accomplish this goal."
The Infusor is a portable, disposable elastomeric infusion device designed to provide a slow, continuous administration of medication given as a result of a surgical procedure. The system then can stay with the patient during recovery and rehabilitation. The device's benefits, therefore, fit well with Zimmer's objectives to help orthopaedic surgical patients reduce the length of their hospital stay and speed their rehabilitation. This is especially true when coordinated with Zimmer Minimally Invasive Solutions(TM) (MIS(TM)) Procedures and Technologies. Zimmer expects to begin selling the system in the first quarter of 2005.
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer is the worldwide #1 pure-play orthopaedic leader in the design, development, manufacture and marketing of reconstructive and spinal implants, trauma and related orthopaedic surgical products. In October 2003, the Company finalized its acquisition of Centerpulse AG, a Switzerland based orthopaedics company and the leader in the European reconstructive market. The new Zimmer has operations in more than 24 countries around the world and sells products in more than 80 countries. As a result of the acquisition of Centerpulse, reported 2003 sales were $1.9 billion. Full-year 2003 pro forma worldwide sales of Zimmer and Centerpulse were approximately $2.6 billion. The new Zimmer is supported by the efforts of more than 6,500 employees.
Visit Zimmer on the worldwide web at http://www.zimmer.com/
Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to, our ability to successfully integrate Centerpulse AG and Implex Corp., the outcome of the pending informal SEC investigation of Centerpulse accounting, price and product competition, rapid technological development, demographic changes, dependence on new product development, the mix of our products and services, supply and prices of raw materials and products, customer demand for our products and services, control of costs and expenses, our ability to form and implement alliances, international growth, governmental laws and regulations affecting our U.S. and international businesses, including tax obligations and risks, product liability and intellectual property litigation losses, reimbursement levels from third-party payors, general industry and market conditions and growth rates and general domestic and international economic conditions including interest rate and currency exchange rate fluctuations. For a further list and description of such risks and uncertainties, see the disclosure materials filed by Zimmer with the U.S. Securities and Exchange Commission. Zimmer disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.
Zimmer Holdings, Inc.
CONTACT: Media: Brad Bishop, +1-574-372-4291,email@example.com , Investors: Marc Ostermann, +1-574-371-8515,firstname.lastname@example.org , or Sam Leno, +1-574-372-4790,email@example.com , all of Zimmer Holdings, Inc.